Atlas Trials

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

Clinical trial NCT04367090 · COMPLETED

Trial details

NCT number
NCT04367090
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2020-05-28
Primary completion
2022-08-10
Enrollment
97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.